AbCellera and Vertex Pharmaceuticals have entered a collaboration to develop multispecific T-cell engagers for autoimmune diseases. AbCellera will lead early discovery, while Vertex will fund development under a deal that includes $28 million upfront, milestone payments, and royalties.
Written By: Nalam Karthik, PharmD
Reviewed By: Pharmacally Editorial Team
AbCellera and Vertex Pharmaceuticals have entered into a strategic collaboration to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other targeted conditions.
The agreement combines AbCellera’s integrated antibody discovery and engineering platform with Vertex’s global development and commercialization capabilities, aiming to expand the pipeline of next-generation immune therapies.
Collaboration Structure & Financial Terms
Under the terms of the agreement, AbCellera will receive $28 million in upfront payments and remains eligible for additional preclinical, development, regulatory, and commercial milestone payments. AbCellera will also be eligible to receive tiered royalties on future net sales of any approved products resulting from the partnership.
AbCellera will lead antibody discovery and early-stage development using its proprietary TCE platform. Vertex will fund all research and development activities and holds exclusive rights to advance and commercialize any therapeutic multispecific antibodies generated. Beyond initial discovery, the companies may jointly agree for AbCellera to handle cell line development, process development, and Phase 1 clinical manufacturing for individual programs.
Expanding T-Cell Engagers Beyond Oncology
T-cell engagers are engineered multispecific antibodies designed to bring T cells into close proximity with disease-associated cells, triggering a highly targeted immune response. While TCE technology has gained significant traction in oncology, researchers are increasingly applying it to autoimmune diseases to selectively eliminate or modulate pathogenic immune cells without causing broader immune suppression.
AbCellera’s end-to-end TCE platform spans the full discovery-to-clinic pipeline. It incorporates proprietary CD3-binding panels, costimulatory targeting domains, multispecific engineering formats, and high-throughput functional screening designed to optimize potency, selectivity, and manufacturability.
Executive Perspective
“This collaboration reflects our strategy of advancing promising T-cell engager programs through both internal development and high-value external partnerships,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “The agreement leverages our integrated platform capabilities to help support the development of potentially transformative therapies.”
“Mark Bunnage, D.Phil., Executive Vice President and Chief Scientific Officer at Vertex, added: “We view multispecific antibody technologies as a compelling opportunity to expand treatment options for serious diseases. AbCellera’s discovery and engineering capabilities provide a sophisticated foundation for generating novel therapeutics that could address significant unmet medical needs.”
Strategic Impact
The partnership aligns with Vertex’s ongoing strategy to diversify its pipeline beyond core therapeutic areas via targeted external innovation. For AbCellera, the deal validates its TCE technology as a engine for partnered drug discovery while securing near-term funding, milestone eligibility, and long-term royalty potential.
While specific disease targets and clinical timelines have not yet been disclosed, Vertex will assume responsibility for late-stage clinical development and global commercialization for all successful candidates.
Reference
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.